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ABSTRACT Fungal keratitis is a common but severe eye infection in tropical and
subtropical areas of the world. In regions with a temperate climate, the frequency of
infection is rising in patients with contact lenses and following trauma. Early and ad-
equate therapy is important to prevent disease progression and loss of vision. The
management of Fusarium keratitis is complex, and the optimal treatment is not well
defined. We investigated the in vitro activity of chlorhexidine and seven antifungal
agents against a well-characterized collection of Fusarium isolates recovered from
patients with Fusarium keratitis. The fungus culture collection of the Center of Exper-
tise in Mycology Radboudumc/CWZ was searched for Fusarium isolates that were
cultured from cornea scrapings, ocular biopsy specimens, eye swabs, and contact
lens fluid containers from patients with suspected keratitis. The Fusarium isolates
that were cultured from patients with confirmed keratitis were all identified using con-
ventional and molecular techniques. Antifungal susceptibility testing was performed ac-
cording to the EUCAST broth microdilution reference method. The antifungal agents
tested included amphotericin B, voriconazole, posaconazole, miconazole, natamycin,
5-fluorocytosine, and caspofungin. In addition, the activity of chlorhexidine was de-
termined. The fungal culture collection contained 98 Fusarium isolates of confirmed fun-
gal keratitis cases from 83 Dutch patients and 15 Tanzanian patients. The isolates were
collected between 2007 and 2017. Fusarium oxysporum (n 24, 24.5%) was the most
frequently isolated species followed by Fusarium solani sensu stricto (n 18, 18.4%)
and Fusarium petroliphilum (n 11, 11.2%). Amphotericin B showed the most favor-
able in vitro inhibition of Fusarium species followed by natamycin, voriconazole, and
chlorhexidine, while 5-fluorocytosine, posaconazole, miconazole, and caspofungin
showed no relevant inhibiting effect. However, chlorhexidine showed fungicidal ac-
tivity against 90% of F. oxysporum strains and 100% of the F. solani strains. Our
study supports the clinical efficacy of chlorhexidine and therefore warrants its fur-
ther clinical evaluation for primary therapy of fungal keratitis, particularly in low and
middle income countries where fungal keratitis is much more frequent and, cur-
rently, antifungal eye drops are often unavailable.
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Fungal keratitis is a common eye infection in tropical and subtropical areas of theworld. In regions with a temperate climate, fungal keratitis is uncommon but mainly
reported in patients with contact lenses and following trauma. Early therapy is impor-
tant to prevent disease progression or dissemination. A major complication of fungal
keratitis is monocular blindness, especially in tropical low and middle income countries
(LMIC), where significant delay in diagnosis and simply the unavailability of antifungals
are common. Most cases of fungal keratitis are caused by Fusarium species (1, 2), which
are ubiquitous fast-growing hyalohyphomycetes that are present in soil, water, and
plants. The most common route of infection is by (micro)trauma or disruptive ocular
surface disease, as filamentous fungi are unable to penetrate intact cornea.
The taxonomy of the Fusarium order is complex and still not well defined. Molecular
techniques have shown that the common medically relevant species, Fusarium solani
and Fusarium oxysporum, consist of multiple (sub)species (3). Although in vitro antifun-
gal susceptibility patterns of Fusarium species may vary greatly within each species,
most species show high MICs to the currently licensed antifungals (4–7). The European
Committee on Antimicrobial Susceptibility Testing (EUCAST) has not defined epidemi-
ological cutoff (ECOFF) values and clinical breakpoints for Fusarium species. In 2015,
Espinel-Ingroff et al. published epidemiological cutoff values (ECVs) based on the
Clinical and Laboratory Standards Institute (CLSI) broth dilution method for antifungal
susceptibility testing (AFST) (8). As topical antifungal therapy is important for fungal
keratitis management, a meaningful classification of isolates as resistant or susceptible
is challenging. These factors complicate the management of Fusarium keratitis (9), and
the optimal treatment is not well defined.
Currently, a 0.02% chlorhexidine solution is used for the treatment of Acanthamoeba
keratitis. A few studies have indicated that the disinfectant chlorhexidine might be an
effective, affordable, and accessible treatment for fungal keratitis, which could benefit
millions of people who currently have no options (10, 11). The meta-analysis in the
Cochrane systematic review written by FlorCruz and Evans show that chlorhexidine has
a better clinical outcome than natamycin and voriconazole (12). To our knowledge,
there are no published data describing the MICs of chlorhexidine for Fusarium species.
In this study, we investigated the in vitro activity of chlorhexidine and seven antifungal
agents against a molecularly characterized set of Fusarium isolates recovered from
patients with keratitis.
RESULTS
The fungal culture collection contained 98 Fusarium isolates from 83 patients with
keratitis from the Netherlands and 15 with keratitis from Tanzania. The isolates were
collected between 2007 and 2017. The first Fusarium isolate per patient was tested.
Molecular identification showed that F. oxysporum (n 24, 24.5%) was the most
frequently isolated species followed by F. solani sensu stricto (n 18, 18.4%) and
Fusarium petroliphilum (n 11, 11.2%). Based on the assignment of the isolates to
the according species complex, as described by Salah et al. (3), the most frequently
encountered complexes were F. solani species complex (FSSC; n 43, 43.9%), F.
oxysporum species complex (FOSC; n 24, 24.5%), Fusarium fujikuroi species complex
(FFSC; n 16, 16.3%) and Fusarium dimerum species complex (FDSC; n 12, 12.2%).
One isolate could not be assigned to any species complex or species and appears to be
a new Fusarium species.
The MIC distributions for the various species and species complexes are shown in
Tables 1 and 2. In vitro amphotericin B was the most active antifungal drug followed by
natamycin, voriconazole, posaconazole, and miconazole. Chlorhexidine showed activity
against all species at a concentration of 8 to 32 mg/liter, which corresponds with
1.56 103% to 6.25 103%. 5-Fluorocytosine showed no in vitro activity.
Statistics. The median MICs and the MIC distributions of 5-fluorocytosine and
caspofungin showed no differences between any of the groups.
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The MIC distributions of amphotericin B showed significant differences between the
species complexes (Kruskal Wallis test, P 0.002). FDSC differed significantly from FSSC
and from FFSC.
For voriconazole, the median MICs and the MIC distributions showed significant
differences between the species complexes (P  0.006 and P  0.000, respectively,
Kruskal Wallis test). FSSC differed significantly from FOSC, from FFSC, and from FDSC.
The MIC distributions of posaconazole and miconazole showed significant differ-
ences between the species complexes (P  0.000 and P  0.001, respectively, Kruskal
Wallis test). For posaconazole and miconazole, FFSC differed significantly from FSSC
and from FOSC.
The median MICs of natamycin were not different between the species complex (SC)
groups (P  0.747, Kruskal-Wallis). On the other hand, the MIC distributions of nata-
mycin differed significantly between the species complexes (P  0.015, Kruskal Wallis
test). FDSC differed significantly from FSSC, from FOSC, and from FFSC.
The median MICs and the MIC distributions of chlorhexidine showed significant
differences between the species complexes (P  0.000 and P  0.000, respectively,
Kruskal Wallis test). FSSC differed significantly from FOSC, from FFSC, and from FDSC.
TABLE 1Molecularly identified Fusarium keratitis isolates and their susceptibility profiles to eight antifungal agents, including
chlorhexidine and natamycin
Fusarium species (n)
MIC (%) (median
[range]) MIC (mg/liter) (median [range])a
MECb mg/liter
(median [range])
CHX CHX AMB VCZ 5-FC MCZ NAT POS CASc
Fusarium species (1) 0.003 16 0.5 2 32 16 8 16 16
F. falciforme (7) 0.006 (0.002–0.006) 32 (8–32) 2 (1–8) 16 (8–16) 32 (32) 16 (16) 8 (8–16) 16 (16) 16 (16)
F. keratoplasticum (7) 0.003 (0.002–0.006) 16 (8–32) 4 (2–4) 8 (4–16) 32 (32) 16 (16) 4 (4–8) 16 (16) 16 (0.5–16)
F. petroliphilum (11) 0.003 (0.002–0.006) 16 (8–32) 2 (0.5–4) 8 (4–16) 32 (32) 16 (16) 4 (4–8) 16 (16) 16 (2–16)
F. solani (18) 0.006 (0.002–0.006) 32 (8–32) 2 (0.063–16) 8 (4–16) 32 (32) 16 (8–16) 8 (4–16) 16 (8–16) 16 (4–32)
F. oxysporum (24) 0.002 (0.0002–0.012) 8 (1–64) 2 (0.25–16) 4 (2–16) 32 (0.063–32) 16 (16) 8 (4–8) 16 (16) 16 (0.063–32)
F. musae (1) 0.003 16 2 4 32 8 8 1 16
F. verticillioides (3) 0.003 (0.001–0.003) 16 (4–16) 2 (1–8) 2 (1–2) 32 (32) 1 (0.25–8) 8 (2–8) 0.5 (0.25–1) 16 (16)
F. proliferatum (7) 0.002 (0.001–0.012) 8 (4–64) 2 (1–4) 4 (2–8) 32 (32) 16 (16) 8 (4–8) 4 (2–16) 16 (16)
F. ramigenum (1) 0.003 16 4 1 32 16 4 1 16
F. sacchari (1) 0.002 8 2 1 32 4 8 0.25 16
F. lactis (3) 0.002 (0.002–0.003) 8 (8–16) 2 (0.5–4) 4 (2–8) 32 (32) 16 (16) 8 (8) 16 (2–16) 16 (16)
F. equiseti (1) NPd NP 1 8 NP NP NP 16 32
F. dimerum (8) 0.002 (0.002–0.003) 8 (8–16) 1 (0.5–2) 8 (4–8) 32 (32) 16 (16) 4 (4–16) 16 (16) 16 (2–16)
F. delphinoides (4) 0.001 (0.001–0.002) 4 (4–8) 0.5 (0.125–1) 2 (2) 32 (32) 16 (16) 4 (2–4) 8 (1–16) 16 (2–16)
F. ambrosium (1) 0.006 32 2 16 32 16 8 16 1
aCHX, chlorhexidine; AMB, amphotericin B; VCZ, voriconazole; 5FC, 5-fluorocytosine; MCZ, miconazole; NAT, natamycin; POS, posaconazole.
bMEC, minimal effective concentration.
cCAS, caspofungin.
dNP, susceptibility testing for this antifungal agent was not performed.
TABLE 2 Fusarium keratitis isolates assigned according to the species complex and their susceptibility profile to eight antifungal agents,
including chlorhexidine and natamycin
Fusarium species
complex (n)a
MIC (%) (median
[range]) MIC (mg/liter) (median [range])b
MECc mg/liter
(median [range])
CHX CHX AMB VCZ 5-FC MCZ NAT POS CASd
Unknown (1) 0.003 16 0.5 2 32 16 8 16 16
FSSC (43) 0.003 (0.002–0.006)e 16 (8–32) 2 (0.063–16) 8 (4–16)e 32 (32) 16 (8–16) 8 (4–16) 16 (8–16) 16 (0.5–32)
FOSC (24) 0.002 (0.002–0.012) 8 (2–64) 2 (0.25–16) 4 (2–16) 32 (0.063–32) 16 (16) 8 (4–8) 16 (16) 16 (0.063–32)
FFSC (16) 0.002 (0.001–0.012) 8 (4–64) 2 (0.5–8) 4 (1–8) 32 (32) 16 (0.25–16)e 8 (2–8) 2 (0.25–16)e 16 (16)
FIESC (1) NPf NP 1 8 NP NP NP 16 32
FDSC (12) 0.002 (0.0008–0.003) 8 (4–16) 1 (0.125–2)e 8 (2–8) 32 (32) 16 (16) 4 (2–16)e 16 (1–16) 16 (2–16)
AFC (1) 0.006 32 2 16 32 16 8 16 1
aFSSC, F. solani species complex; FOSC, F. oxysporum species complex; FFSC, F. fujikuroi species complex; FIESC, F. incarnatum-equiseti species complex; FDSC, F.
dimerum species complex; AFC, Ambrosia Fusarium clade.
bCHX, chlorhexidine; AMB, amphotericin B; VCZ, voriconazole; 5FC, 5-fluorocytosine; MCZ, miconazole; NAT, natamycin; POS, posaconazole.
cMEC, minimal effective concentration.
dCAS, caspofungin.
eSignificant difference of the median and or distribution range between the groups of species complex.
fNP, susceptibility testing for this antifungal agent was not performed.
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MIC values of posaconazole, miconazole, 5-fluorocytosine, and caspofungin were
high, and so determining the minimal fungicidal concentration (MFC) of these agents
was deemed clinically not relevant.
In vitro amphotericin B exhibited fungicidal effect on 60% of the F. oxysporum strains
and 70% of the F. solani strains; the remainder of the strains showed a fungistatic effect
(Fig. 1). Natamycin was fungicidal against 80% of the F. oxysporum strains. However, in
F. solani strains, natamycin was mostly fungistatic; in only 30%, it acted as a fungicidal.
Voriconazole was fungicidal against 30% of the F. oxysporum strains and 50% of the F.
solani strains. Chlorhexidine showed fungicidal activity against 90% of F. oxysporum
strains and 100% of the F. solani strains.
DISCUSSION
Chlorhexidine showed broad in vitro activity against all Fusarium species tested and,
compared with the antifungal agents, showed the broadest fungicidal activity against
the two species tested. Although it is likely that chlorhexidine is fungicidal in other
Fusarium species, this was not tested. For chlorhexidine, 95% of the 20 Fusarium isolates
were killed at concentrations far below the 0.02% and 0.2% concentrations, of which,
the 0.02% concentration for eye drops is already commonly used by ophthalmologists
for treatment of Acanthamoeba keratitis. Another important advantage of chlorhexi-
dine gluconate solution is the broad antimicrobial spectrum, including against Gram-
positive and Gram-negative bacteria, lipid-enveloped viruses, and Acanthamoeba
(12, 13).
FIG 1 The proportions of fungicidal (blue) and fungistatic (green) in vitro effects of amphotericin B, natamycin, voriconazole, and the
disinfectant chlorhexidine depicted for Fusarium oxysporum (n 10) and Fusarium solani (n 10), all of which were isolated from patients
with fungal keratitis.
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A limited number of clinical trials have studied the effectiveness of chlorhexidine
gluconate for the treatment of fungal keratitis. The aim of one trial was to find the most
effective dose of chlorhexidine (14). In comparison to the response with natamycin, the
relative efficacy in a patient without prior antifungal treatment was 1.17 with chlo-
rhexidine 0.05%, 1.43 with chlorhexidine 0.1%, and 2.00 with chlorhexidine 0.2%. Their
fungal isolates were not subjected to molecular identification and susceptibility testing.
The second study by Rahman et al. (10) showed a relative efficacy of 1.85 (confidence
interval [CI], 1.01 to 3.39; P  0.04) with chlorhexidine 0.2% in comparison to natamy-
cin. Of the nonsevere ulcers, 66.7% were healed at day 21 with chlorhexidine and 36.0%
with natamycin. However, this trial was not double blinded due to the fact that
personnel could identify the selected treatment because the solutions of chlorhexidine
and natamycin were visibly different (10). The susceptibility testing was performed with
a nonreference well diffusion method (0.2% chlorhexidine, 2.5% natamycin, 1% eco-
nazole). The concentration of natamycin used was 2.5%, which is half the current
standard therapeutic concentration of 5%. In addition, the method of identification of
the strains was also not mentioned.
In the Netherlands, the available antifungal agents which can be used as eye drops
are amphotericin B 0.15% (1,500 mg/liter), voriconazole 1% (10,000 mg/liter), and the
disinfectant chlorhexidine 0.02% (200 mg/liter). These formulas are not commercially
available but are prepared by hospital pharmacists on request. In other countries,
natamycin (5% suspension; 50,000 mg/liter) is available and frequently used in the
setting of fungal keratitis (2, 10–12, 15–20). These concentrations exceed by far the in
vitro determined MICs of the Fusarium isolates (Tables 1 and 2). However, effectiveness
depends on many factors, including the ability of the compound to penetrate ocular
tissues, local bioavailability, and drug toxicity.
The most important route of penetration of topical antifungals into ocular tissue is
through the cornea, mostly by diffusion. The polyenes, amphotericin B and natamycin,
are compounds with a high molecular mass (i.e., 500 Da) and, as a consequence,
barely penetrate intact cornea epithelium (21). This leads to the necessity of regularly
performing abrasions of the cornea during treatment with amphotericin B. In high
doses, amphotericin B can be toxic to the cornea, but the 0.15% solution is well
tolerated (21). Due to the viscous nature of natamycin suspension and its poor
penetration, it is only suitable for treatment of superficially located keratomycosis.
Furthermore, compounds that are lipophilic can penetrate across the corneal stroma,
while hydrophilic agents are able to penetrate all the layers of the cornea.
There is little known about the corneal penetration of the cationic antisepticum
chlorhexidine gluconate. In a small animal study, Vontobel et al. showed that the
compound did not penetrate through the intact or mechanically damaged cornea into
the anterior chamber (22). It appears that chlorhexidine accumulates within the cornea,
explaining the need to treat deep-seated Acanthamoeba for a long time.
Amphotericin B showed the most favorable in vitro inhibition of Fusarium species,
followed by natamycin, voriconazole, and chlorhexidine, while 5-fluorocytosine, po-
saconazole, miconazole, and caspofungin showed no relevant inhibiting effect. How-
ever, chlorhexidine showed fungicidal activity against 90% of F. oxysporum strains and
100% of the F. solani strains.
The differences in AFST between isolates belonging to the same species complex
justifies conducting molecular identification to the species complex level. In general,
the species belonging to the FDSC and the FFSC are more susceptible to chlorhexidine,
amphotericin B, natamycin, voriconazole, and posaconazole (only FFSC). These differ-
ences cannot be predicted by identification based on conventional methods, because
the characteristics of morphology and microscopy are not species specific.
Our study supports the clinical efficacy of chlorhexidine and therefore warrants its
further clinical evaluation for primary therapy of fungal keratitis, particularly in LMIC
where fungal keratitis is much more frequent and, currently, antifungal eye drops are
often unavailable. Further studies should investigate the in vitro interaction of chlo-
In Vitro Susceptibility of Fusarium Antimicrobial Agents and Chemotherapy
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rhexidine with antifungal agents to support alternate administration and combination
therapy.
MATERIALS AND METHODS
The fungus culture collection of the Center of Expertise in Mycology Radboudumc/CWZ was searched
for Fusarium isolates that were cultured from cornea scrapings, ocular biopsy specimens, eye swabs, and
contact lens fluid containers from patients with suspected keratitis. All isolates had been identified to the
genus level using conventional techniques. For accurate species identification, sequencing of the TEF1
gene was performed (3).
Antifungal susceptibility testing was performed according to the EUCAST broth microdilution
reference method (23, 24). The antifungal agents tested included amphotericin B (Bristol Myers Squibb),
voriconazole (Pfizer), posaconazole (Merck & Co), miconazole (Janssen Cilag), natamycin (Sigma-Aldrich),
5-fluorocytosine (Hoffman la Roche), and caspofungin (Merck & Co). In addition, the activity of chlo-
rhexidine (Pharmaline) was determined. The test range of the antifungal agents was 0.02 to 16 mg/liter
for amphotericin B, voriconazole, posaconazole, miconazole, caspofungin, and natamycin, and 0.03 to
32 mg/liter for 5-fluorocytosine. For chlorhexidine, a concentration range of 1 to 1,024 mg/liter was used,
which corresponds to a range of 0.000195% to 0.2%. All antifungal agents and chlorhexidine were
dissolved in RPMI 1640 supplemented with glucose to a final concentration of 2%. The MICs were
determined with an inverted mirror after 48 h at 35°C as the lowest drug concentration with complete
inhibition of growth visible by eye for amphotericin B, voriconazole, posaconazole, miconazole, nata-
mycin, 5-fluorocytosine, and chlorhexidine. The endpoint for echinocandins was the minimal effective
concentration (MEC). The MEC for caspofungin was determined with an inverted microscope after 48 h
at 35°C as the lowest drug concentration in which abnormal, short, and branched hyphal clusters were
observed in contrast to the long, unbranched, elegant hyphal elements that were visible in the growth
control well. Aspergillus fumigatus ATCC 204305 and Aspergillus flavus ATCC 204304 were used as quality
control strains as recommended by the EUCAST (23).
Ten F. oxysporum and 10 F. solani isolates were used to determine the minimal fungicidal concen-
tration (MFC) for the antifungal agents and chlorhexidine. After reading the MICs at 48 h, the 96-wells
plates were shaken to loosen the fungal elements. Thereafter, 20 l from all the wells with no visible
growth and 20 l from the growth control were plated on Sabouraud agar (Oxoid). The plates were
incubated for 24 and 48 h at 35°C. The MFC was determined as the lowest drug concentration which led
to 99% to 99.5% growth inhibition compared to the growth control. Antifungal agents were considered
fungicidal when the MIC value was no more than two dilution steps lower than the MFC (25). If the
difference between MIC and MFC was2 dilution steps, the antifungal agent was classified as fungistatic
(25).
Statistical analysis was performed with IBM SPSS Statistics 24. In vitro susceptibility differences
between Fusarium species and differences between species complexes were tested with a nonparametric
test (one-way analysis of variance [ANOVA], Kruskal-Wallis). A P value of 0.05 was determined as
significant. To correct for multitesting in the search for which groups differed from each other, the P
value was adjusted according to Bonferroni’s correction method (e.g., significance level [0.05] divided
by the number of tests needed). Bonferroni’s correction for the species groups was a P value of 0.0011;
for the species complex groups, Bonferroni’s P value was 0.0083. Species and species complexes with
only one isolate where not taken into account in the statistical analysis. For every antifungal or antiseptic
agent, we tested for significant differences between the species complexes by comparing the median
MICs or percentages of the concentration and comparing the distributions between the groups. After this
comparison, the groups which were responsible for the significant difference were determined by
comparing one group to another group with the Mann-Whitney U test.
The samples from Dutch participants were collected during the routine standard of care. Therefore,
we did not need their informed consent in accordance with the Dutch Ethics Committee of the Radboud
University Medical Center.
The collection of samples from Tanzanian participants was approved by the Ethics Committees of the
National Institute for Medical Research, Tanzania, and the London School of Hygiene & Tropical Medicine,
United Kingdom. Informed consent was obtained from all participants.
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